Retrospective Analysis of Independent Predictors of Progression-free Survival in Patients with EGFR Mutation-positive Advanced Non-small Cell Lung Cancer Receiving First-line Osimertinib

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2022 Sep 9

PMID 36082812

Authors

Shuhei Teranishi

Chihiro Sugimoto

Satoshi Nagaoka

Hirokazu Nagayama

Wataru Segawa

Atsushi Miyasaka

Shuntaro Hiro

Yukihito Kajita

Chihiro Maeda

Nobuaki Kobayashi

Masaki Yamamoto

Makoto Kudo

Takeshi Kaneko

Affiliations

Soon will be listed here.

Abstract

Background: Clinically measurable factors affecting the progression-free survival (PFS) of patients receiving osimertinib as first-line therapy for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC) have not yet been established.

Methods: We retrospectively reviewed the medical records of 61 patients treated with osimertinib as primary therapy for EGFR mutation-positive advanced NSCLC at Yokohama City University Medical Center between August 2018 and March 2022. Our objective was to identify the independent predictors of PFS.

Results: The median age of participants was 74 years. Overall, 73.8% had good (0-1) Eastern Cooperative Oncology Group performance status (PS), and 98.4% had histology of adenocarcinoma. The EGFR mutation was exon19 deletion in 52.5% and exon21 L858R in 44.3% of patients. Programmed death-ligand 1 tumor proportion score >50% was observed in 21.3% and liver metastasis in 9.9% of patients. Median PFS was 19.5 months (95% confidence interval [CI]: 10.6-31.6), and overall survival was not reached. The objective response rate was 68.9%, and disease control rate was 93.4%. Multivariate analysis showed that poor PS (2-4) negatively impacted PFS (hazard ratio, 3.79; 95% CI: 1.46-9.87; p = 0.006). Median PFS in the good PS and poor PS groups was 20.4 months (95% CI: 12.4-not evaluable) and 7.2 months (95% CI: 7.2-19.5), respectively. Interstitial lung disease of all grades and grade 3 was observed as an adverse event in 6.6 and 4.9% of patients, respectively.

Conclusion: Poor PS was associated with poor prognosis in patients with EGFR mutation-positive advanced NSCLC treated with osimertinib as first-line therapy.

Citing Articles

Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.

Taniguchi Y, Tamiya A, Osuga M, Isa S, Nakamura K, Mizumori Y Invest New Drugs. 2025; 43(1):101-107.

PMID: 39789369 DOI: 10.1007/s10637-024-01500-9.

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.

Chen H, Chen C, Liao W, Lin Y, Chen H, Hsia T BMC Pulm Med. 2024; 24(1):517.

PMID: 39415161 PMC: 11481380. DOI: 10.1186/s12890-024-03336-8.

Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors.

Moiseenko F, Kuligina E, Elsakova E, Imyanitov E Future Oncol. 2024; 20(31):2397-2407.

PMID: 39229777 PMC: 11520547. DOI: 10.1080/14796694.2024.2386925.

Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.

Taniguchi Y, Tamiya A, Osuga M, Harada D, Isa S, Nakamura K BMC Pulm Med. 2024; 24(1):407.

PMID: 39182046 PMC: 11344331. DOI: 10.1186/s12890-024-03212-5.

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations.

Takeyasu Y, Yoshida T, Masuda K, Matsumoto Y, Shinno Y, Okuma Y JTO Clin Res Rep. 2024; 5(2):100636.

PMID: 38361742 PMC: 10867446. DOI: 10.1016/j.jtocrr.2024.100636.

References

Hsu K, Tseng J, Yang T, Chen K, Su K, Yu S . PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep. 2022; 12(1):9753. PMC: 9192769. DOI: 10.1038/s41598-022-13102-7. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Chang Y, Chen Y, Lai C, Lin C, Fang W, Huang C . The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PLoS One. 2017; 12(6):e0178676. PMC: 5462397. DOI: 10.1371/journal.pone.0178676. View

Su S, Dong Z, Xie Z, Yan L, Li Y, Su J . Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. J Thorac Oncol. 2018; 13(11):1668-1675. DOI: 10.1016/j.jtho.2018.07.016. View

Teranishi S, Sugimoto C, Nagaoka S, Nagayama H, Segawa W, Miyasaka A . Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib. Thorac Cancer. 2022; 13(19):2741-2750. PMC: 9527177. DOI: 10.1111/1759-7714.14608. View

Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N . Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated -mutated advanced non-small cell lung cancer: a prospective observational study. Transl Lung Cancer Res. 2021; 10(8):3582-3593. PMC: 8435385. DOI: 10.21037/tlcr-21-461. View

Yang C, Liao W, Ho C, Chen K, Tsai T, Hsu C . Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer. 2019; 124:110-122. DOI: 10.1016/j.ejca.2019.10.019. View

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

10.

Lorenzi M, Ferro A, Cecere F, Scattolin D, Del Conte A, Follador A . First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist. 2022; 27(2):87-e115. PMC: 9714585. DOI: 10.1002/onco.13951. View

11.

Hsu K, Huang Y, Tseng J, Chen K, Ku W, Su K . High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer. 2019; 127:37-43. DOI: 10.1016/j.lungcan.2018.11.021. View

12.

Zhang Y, Yuan J, Wang K, Fu X, Han X, Threapleton D . The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016; 7(48):78985-78993. PMC: 5346692. DOI: 10.18632/oncotarget.12587. View

13.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

14.

Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R . Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. 2021; 159:144-153. DOI: 10.1016/j.ejca.2021.09.041. View

15.

Haratake N, Misumi T, Yamanaka T, Seto T . Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in -Mutated Lung Cancer. JTO Clin Res Rep. 2021; 1(4):100085. PMC: 8474446. DOI: 10.1016/j.jtocrr.2020.100085. View

16.

Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I . First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009; 27(9):1394-400. DOI: 10.1200/JCO.2008.18.7658. View

17.

Kang M, Park C, Kim S, Yoon S, Suh K, Kim Y . Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Transl Lung Cancer Res. 2021; 10(2):699-711. PMC: 7947423. DOI: 10.21037/tlcr-20-893. View

18.

Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K . Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status. Anticancer Res. 2013; 33(11):5057-64. View

19.

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

20.

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View